Wednesday, 28 September 2016

brompheniramine


Generic Name: brompheniramine (brome feh NEER a meen)

Brand names: BroveX, BroveX CT, Dimetane, Dimetane Extentab, Dimetapp Allergy, Dimetapp Allergy Liquigel, Lodrane 12 Hour, ...show all 28 brand names.


What is brompheniramine?

Brompheniramine is an antihistamine. Brompheniramine blocks the effects of the naturally occurring chemical histamine in the body.


Brompheniramine is used to sneezing; runny nose; itching, watery eyes; hives; rashes; itching; and other symptoms of allergies and the common cold.


Brompheniramine may also be used for purposes other than those listed in this medication guide.


What is the most important information I should know about brompheniramine?


Use caution when driving, operating machinery, or performing other hazardous activities. Brompheniramine may cause dizziness or drowsiness. If you experience dizziness or drowsiness, avoid these activities. Use alcohol cautiously. Alcohol may increase drowsiness and dizziness while taking brompheniramine. Do not crush, chew, or break the extended- or timed-release forms of brompheniramine. Swallow them whole. They are specially formulated to release the medication slowly in the body.

What should I discuss with my healthcare provider before taking brompheniramine?


Do not take brompheniramine if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), phenelzine (Nardil), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects.

Before taking brompheniramine, talk to your doctor if you have



  • glaucoma or increased pressure in the eye;




  • a stomach ulcer;




  • an enlarged prostate, bladder problems or difficulty urinating;




  • an overactive thyroid (hyperthyroidism);




  • hypertension or any type of heart problems; or




  • asthma.



You may not be able to take brompheniramine, or you may require a dosage adjustment or special monitoring during treatment if you have any of the conditions listed above.


Brompheniramine is in the FDA pregnancy category C. This means that it is not known whether brompheniramine will be harmful to an unborn baby. Do not take brompheniramine without first talking to your doctor if you are pregnant or could become pregnant during treatment. Brompheniramine passes into breast milk. Infants are especially sensitive to the effects of antihistamines, and serious side effects could occur in a nursing infant. Do not take brompheniramine without first talking to your doctor if you are nursing a baby. If you are over 60 years of age, you may be more likely to experience side effects from brompheniramine. You may require a lower dose of this medication.

How should I take brompheniramine?


Take brompheniramine exactly as directed on the package or as directed by your doctor. If you do not understand these directions, ask your pharmacist, nurse, or doctor to explain them to you.


Take each dose with a full glass of water.

Brompheniramine can be taken with or without food.


Do not crush, chew, or break the extended- or timed-release forms of brompheniramine. Swallow them whole. They are specially formulated to release the medication slowly in the body.

To ensure that you get a correct dose, measure the liquid form of brompheniramine with a special dose-measuring spoon or cup, not with a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist where you can get one.


Do not take more of this medication than is prescribed or is recommended on the package. The maximum amount of brompheniramine that you should take in 1 day is 24 mg. The regular-release tablets and the syrup are usually taken every 4 to 6 hours as needed (four to six times a day). The sustained-release tablets and capsules are usually taken every 8 to 12 hours as needed (two or three times a day). If your symptoms do not improve, or if they worsen, contact your healthcare provider. Store brompheniramine at room temperature away from moisture and heat.

What happens if I miss a dose?


Take the missed dose as soon as you remember. However, if it is almost time for the next dose, skip the missed dose and take only the next regularly scheduled dose. Do not take a double dose of this medication unless otherwise directed by your doctor.


What happens if I overdose?


Seek emergency medical attention if an overdose is suspected.

Symptoms of a brompheniramine overdose may include extreme sleepiness, confusion, weakness, ringing in the ears, blurred vision, large pupils, dry mouth, flushing, fever, shaking, insomnia, hallucinations, and possibly seizures.


What should I avoid while taking brompheniramine?


Do not take other over-the-counter cough, cold, allergy, diet, pain, or sleep medications while taking brompheniramine without first talking to your pharmacist or doctor. Other medications may also contain brompheniramine or other similar drugs, and you may accidentally take too much of these medicines.


Brompheniramine may increase the effects of other drugs that cause drowsiness, including antidepressants, alcohol, other antihistamines, pain relievers, anxiety medicines, seizure medicines, and muscle relaxants. Dangerous sedation, dizziness, or drowsiness may occur if brompheniramine is taken with any of these medications.


Use alcohol cautiously. Alcohol may increase drowsiness and dizziness while taking brompheniramine.

Brompheniramine side effects


Stop taking brompheniramine and seek emergency medical attention if you experience a rare but serious allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives).

Other, less serious side effects may be more likely to occur. Continue to take brompheniramine and talk to your doctor if you experience



  • sleepiness, fatigue, or dizziness;




  • headache;




  • dry mouth; or




  • difficulty urinating or an enlarged prostate.



Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome. You may report side effects to FDA at 1-800-FDA-1088.


Brompheniramine Dosing Information


Usual Adult Dose for Cold Symptoms:

Immediate Release: 4 mg to 8 mg orally every 6 hours as needed. The duration of action varies from patient to patient. Many patients will require dosing only twice daily.

Extended Release: 6 mg to 12 mg extended release orally twice daily as needed. The duration of action varies from patient to patient. Many patients will require dosing only once a day, preferably at bedtime to avoid drowsiness.

Maximum oral dose 24 mg/day.

Usual Adult Dose for Allergic Rhinitis:

Immediate Release: 4 mg to 8 mg orally every 6 hours as needed. The duration of action varies from patient to patient. Many patients will require dosing only twice daily.

Extended Release: 6 mg to 12 mg extended release orally twice daily as needed. The duration of action varies from patient to patient. Many patients will require dosing only once a day, preferably at bedtime to avoid drowsiness.

Maximum oral dose 24 mg/day.

Usual Adult Dose for Urticaria:

Immediate Release: 4 mg to 8 mg orally every 6 hours as needed. The duration of action varies from patient to patient. Many patients will require dosing only twice daily.

Extended Release: 6 mg to 12 mg extended release orally twice daily as needed. The duration of action varies from patient to patient. Many patients will require dosing only once a day, preferably at bedtime to avoid drowsiness.

Maximum oral dose 24 mg/day.

Usual Adult Dose for Allergic Reaction:

Immediate Release: 4 mg to 8 mg orally every 6 hours as needed. The duration of action varies from patient to patient. Many patients will require dosing only twice daily.

Extended Release: 6 mg to mg 12 mg extended release orally twice daily as needed. The duration of action varies from patient to patient. Many patients will require dosing only once a day, preferably at bedtime to avoid drowsiness.

Maximum oral dose 24 mg/day.

IV, IM, subcutaneous: 5 mg to 20 mg every 6 to 12 hours. Duration of action is 3 to 12 hours.
Maximum parenteral dose 40 mg/day.

Usual Pediatric Dose for Allergic Rhinitis:

Immediate Release:
0.125 mg/kg/dose orally every 6 hours. Maximum dose: 6 mg to 8 mg/day.

2 to 6 years:
Extended Release suspension:
2 mg orally twice daily, not to exceed 2 doses in 24 hours.

6 to 12 years:
Immediate Release:
2 mg to 4 mg orally every 6 to 8 hours. Maximum dose 12 to 16 mg/day.
Extended Release suspension:
4 mg orally twice daily, not to exceed 2 doses in 24 hours.

> 12 years:
Immediate Release:
4 mg to 8 mg orally every 6 hours as needed. The duration of action varies from patient to patient. Many patients will require dosing only twice daily.
Extended Release:
6 mg to 12 mg sustained release orally twice daily as needed. The duration of action varies from patient to patient. Many patients will require dosing only once a day, preferably at bedtime to avoid drowsiness.

Maximum oral dose 24 mg/day.

Usual Pediatric Dose for Cold Symptoms:

Immediate Release:
0.125 mg/kg/dose orally every 6 hours. Maximum dose: 6 mg to 8 mg/day.

2 to 6 years:
Extended Release suspension:
2 mg orally twice daily, not to exceed 2 doses in 24 hours.

6 to 12 years:
Immediate Release:
2 mg to 4 mg orally every 6 to 8 hours. Maximum dose 12 to 16 mg/day.
Extended Release suspension:
4 mg orally twice daily, not to exceed 2 doses in 24 hours.

> 12 years:
Immediate Release:
4 mg to 8 mg orally every 6 hours as needed. The duration of action varies from patient to patient. Many patients will require dosing only twice daily.
Extended Release:
6 mg to 12 mg sustained release orally twice daily as needed. The duration of action varies from patient to patient. Many patients will require dosing only once a day, preferably at bedtime to avoid drowsiness.

Maximum oral dose 24 mg/day.

Usual Pediatric Dose for Urticaria:

Immediate Release:
0.125 mg/kg/dose orally every 6 hours. Maximum dose: 6 mg to 8 mg/day.

2 to 6 years:
Extended Release suspension:
2 mg orally twice daily, not to exceed 2 doses in 24 hours.

6 to 12 years:
Immediate Release:
2 mg to 4 mg orally every 6 to 8 hours. Maximum dose 12 to 16 mg/day.
Extended Release suspension:
4 mg orally twice daily, not to exceed 2 doses in 24 hours.

> 12 years:
Immediate Release:
4 mg to 8 mg orally every 6 hours as needed. The duration of action varies from patient to patient. Many patients will require dosing only twice daily.
Extended Release:
6 mg to 12 mg sustained release orally twice daily as needed. The duration of action varies from patient to patient. Many patients will require dosing only once a day, preferably at bedtime to avoid drowsiness.

Maximum oral dose 24 mg/day.

Usual Pediatric Dose for Allergic Reaction:

Immediate Release:
0.125 mg/kg/dose orally every 6 hours. Maximum dose: 6 mg to 8 mg/day.

2 to 6 yrs:
Extended Release Suspension:
2.5 mg extended release orally twice daily as needed. The duration of action varies from patient to patient. Many patients will require dosing only once a day, preferably at bedtime to avoid drowsiness.

6 to 12 years:
Immediate Release:
2 mg to 4 mg orally every 6 to 8 hours. Maximum dose 12 to 16 mg/day.
Extended Release Suspension:
5 mg extended release orally twice daily as needed. The duration of action varies from patient to patient. Many patients will require dosing only once a day, preferably at bedtime to avoid drowsiness.


> 12 years:
Immediate Release:
4 mg orally every 6 hours as needed. The duration of action varies from patient to patient. Many patients will require dosing only twice daily.
Extended Release:
6 mg to 12 mg extended release orally twice daily as needed. The duration of action varies from patient to patient. Many patients will require dosing only once a day, preferably at bedtime to avoid drowsiness.

Maximum oral dose 24 mg/day.

IM, IV, subcutaneous :
0.5 mg/kg/day divided every 6 to 8 hours.

> 12 years:
5 mg to 20 mg every 6 to 12 hours. Duration of action is 3 to 12 hours.
Maximum parenteral dose 40 mg/day.


What other drugs will affect brompheniramine?


Do not take brompheniramine if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), phenelzine (Nardil), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects.

Do not take other over-the-counter cough, cold, allergy, diet, pain, or sleep medications while taking brompheniramine without first talking to your pharmacist or doctor. Other medications may also contain brompheniramine or other similar drugs, and you may accidentally take too much of these medicines.


Brompheniramine may increase the effects of other drugs that cause drowsiness, including antidepressants, alcohol, other antihistamines, pain relievers, anxiety medicines, seizure medicines, and muscle relaxants. Dangerous sedation, dizziness, or drowsiness may occur if brompheniramine is taken with any of these medications.


Drugs other than those listed here may also interact with brompheniramine. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines, including vitamins, minerals, and herbal products.



More brompheniramine resources


  • Brompheniramine Side Effects (in more detail)
  • Brompheniramine Use in Pregnancy & Breastfeeding
  • Drug Images
  • Brompheniramine Drug Interactions
  • Brompheniramine Support Group
  • 6 Reviews for Brompheniramine - Add your own review/rating


  • Brompheniramine 12-Hour Sustained-Release Tablets MedFacts Consumer Leaflet (Wolters Kluwer)

  • Brompheniramine Professional Patient Advice (Wolters Kluwer)

  • Brompheniramine Maleate, Dexbrompheniramine Maleate Monograph (AHFS DI)

  • Brovex Suspension MedFacts Consumer Leaflet (Wolters Kluwer)

  • Brovex CT Chewable Tablets MedFacts Consumer Leaflet (Wolters Kluwer)

  • Lodrane 24 24-Hour Sustained-Release Capsules MedFacts Consumer Leaflet (Wolters Kluwer)

  • VaZol Liquid MedFacts Consumer Leaflet (Wolters Kluwer)



Compare brompheniramine with other medications


  • Allergic Reactions
  • Cold Symptoms
  • Hay Fever
  • Urticaria


Where can I get more information?


  • Your pharmacist has more information about brompheniramine written for health professionals that you may read.

See also: brompheniramine side effects (in more detail)


Benzro




Benzro may be available in the countries listed below.


Ingredient matches for Benzro



Benzbromarone

Benzbromarone is reported as an ingredient of Benzro in the following countries:


  • Taiwan

International Drug Name Search

Finural




Finural may be available in the countries listed below.


Ingredient matches for Finural



Finasteride

Finasteride is reported as an ingredient of Finural in the following countries:


  • Germany

International Drug Name Search

Tuesday, 27 September 2016

Claritromycine PCH




Claritromycine PCH may be available in the countries listed below.


Ingredient matches for Claritromycine PCH



Clarithromycin

Clarithromycin is reported as an ingredient of Claritromycine PCH in the following countries:


  • Netherlands

International Drug Name Search

Ramelteon


Class: Anxiolytics, Sedatives, and Hypnotics; Miscellaneous
VA Class: CN300
Chemical Name: N-[2-[8S)-1,6,7,8-Tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl-propanamide
Molecular Formula: C16H21NO2
CAS Number: 196597-26-9
Brands: Rozerem


REMS:


FDA approved a REMS for ramelteon to ensure that the benefits of a drug outweigh the risks. However, FDA later rescinded REMS requirements. See the FDA REMS page () or the ASHP REMS Resource Center ().



Introduction

Melatonin receptor agonist; hypnotic.1 2


Uses for Ramelteon


Insomnia


Management of insomnia characterized by difficulty with sleep onset.1


Decreases sleep latency in patients with transient insomnia.1 2 Decreases sleep latency in patients with chronic insomnia receiving therapy for up to 35 days.1 2 3 4 5


Ramelteon Dosage and Administration


Administration


Oral Administration


Administer orally within 30 minutes of bedtime.1 2


Avoid administration with or immediately after a high-fat meal because of potentially decreased rate of absorption.1 2 (See Food under Pharmacokinetics.)


Dosage


Adults


Insomnia

Oral

8 mg.1 2


Special Populations


Hepatic Impairment


Increased exposure to drug and active metabolite.1 (See Special Populations under Pharmacokinetics.) No specific dosage recommendations at this time.1 However, use with caution in patients with moderate hepatic impairment; avoid use in patients with severe hepatic impairment.1


Renal Impairment


No dosage adjustment necessary in patients with mild, moderate, or severe renal impairment or in those requiring chronic hemodialysis.1


Cautions for Ramelteon


Contraindications



  • Hypersensitivity to ramelteon or any ingredient in the formulation.1



Warnings/Precautions


Warnings


Adequate Patient Evaluation

Sleep disturbances may be a manifestation of a physical and/or psychiatric disorder; carefully evaluate patient before providing symptomatic treatment.1


Failure of insomnia to remit after a reasonable treatment period, exacerbation of insomnia, and/or emergence of new cognitive or behavioral abnormalities may indicate the presence of an underlying psychiatric or physical disorder requiring further patient evaluation.1


Complex Sleep-related Behaviors

Potential risk of complex sleep-related behaviors such as sleep-driving (i.e., driving while not fully awake after ingesting a sedative-hypnotic drug, with no memory of the event), making phone calls, or preparing and eating food while asleep.6


Sensitivity Reactions


Potential risk of anaphylaxis and angioedema; may occur as early as with the first dose of drug.6


Major Toxicities


Psychiatric Effects

Cognitive and behavioral changes reported.1 In primarily depressed patients, exacerbation of depression and suicidal ideation reported following use of hypnotics.1


Immediately evaluate any new psychiatric abnormalities.1


Endocrine Effects

Increased prolactin concentrations reported in patients with chronic insomnia receiving ramelteon 16 mg daily for 6 months.1


Abnormal morning cortisol concentrations (resulting in abnormal corticotropin [ACTH] stimulation test results) reported in 2 patients and prolactinoma reported in 1 patient receiving long-term (up to 12 months) therapy; causal relationship to drug not established.1


If unexplained amenorrhea, galactorrhea, decreased libido, or fertility problems occur, consider evaluating prolactin or testosterone concentrations.1


Abuse Potential and Dependence

No evidence of abuse potential detected following administration of doses up to 20 times the recommended hypnotic dose in patients with a history of drug abuse or dependence.1 2


No evidence of physical dependence.1


Withdrawal

No evidence of a withdrawal syndrome, including rebound insomnia, following discontinuance of long-term therapy (4, 8, or 16 mg daily for up to 35 days).1 2


Residual Effects

Next-day residual effects (reduced immediate/delayed memory recall and increased sluggishness, fatigue, and irritation) detected at weeks 1 and 3 but not week 5 of therapy in adult patients receiving ramelteon 8 mg daily.1 2 Residual effects not detected in a similar study in geriatric patients receiving ramelteon 4 or 8 mg daily.1 2


General Precautions


Long-term Safety

No clinically meaningful changes in laboratory parameters, endocrine tests, vital signs, ECG recordings, or intensity of menstrual bleeding detected in patients with chronic insomnia following up to 1 year of therapy.2 Rebound insomnia not observed following 1 year of therapy.2


Concomitant Diseases

No respiratory depressant effect in patients with mild to moderate COPD.1 Effects in patients with severe COPD (e.g., those with elevated pCO2, those requiring nocturnal oxygen therapy) not studied; use in these patients not recommended.1


No differences in measures of apnea indices observed in patients with mild to moderate obstructive sleep apnea.1 Effects in patients with severe obstructive sleep apnea not studied; use in these patients not recommended.1


Specific Populations


Pregnancy

Category C.1


Lactation

Distributed into milk in rats; not known whether distributed into human milk.1 Use not recommended.1


Pediatric Use

Safety and efficacy not established in pediatric patients.1


Geriatric Use

Increased exposure to drug and active metabolite.1 (See Special Populations under Pharmacokinetics.) However, no overall differences in safety or efficacy relative to younger adults.1


Hepatic Impairment

Use with caution in patients with moderate hepatic impairment; avoid use in patients with severe hepatic impairment.1 (See Special Populations under Pharmacokinetics.)


Common Adverse Effects


Headache, somnolence, dizziness, fatigue, nausea, exacerbation of insomnia, upper respiratory tract infection, diarrhea, myalgia, depression, dysgeusia, arthralgia.1


Interactions for Ramelteon


Metabolized principally by CYP1A2 and, to a lesser extent, by the CYP2C subfamily and by CYP3A4.1


Drugs Affecting Hepatic Microsomal Enzymes


Inhibitors of CYP1A2: Potential pharmacokinetic interaction (substantially increased serum ramelteon concentrations).1 Avoid concomitant use with strong CYP1A2 inhibitors; caution if used concomitantly with less potent CYP1A2 inhibitors.1


Inhibitors of CYP3A4 and CYP2C9: Potential pharmacokinetic interaction (increased serum concentrations of ramelteon and active metabolite).1 Caution if used concomitantly with potent inhibitors of CYP3A4 or CYP2C9.1


Inducers of CYP isoenzymes: Potential pharmacokinetic interaction (decreased serum concentrations of ramelteon and active metabolite).1 Possibly reduced ramelteon efficacy when used concomitantly with potent CYP inducers.1 2


Drugs Metabolized by Hepatic Microsomal Enzymes


Substrates of CYP isoenzymes 1A2, 2C9, 2C19, 2D6, and 3A4: Pharmacokinetic interaction unlikely.1


Specific Drugs













































Drug or Test



Interaction



Comments



Alcohol



Additive sedative effects1



Avoid concomitant use1



Dextromethorphan



Pharmacokinetic interaction unlikely1



Digoxin



Pharmacokinetic interaction unlikely1



Fluconazole



Increased peak serum concentrations and AUC of ramelteon and active metabolite1



Use concomitantly with caution1



Fluoxetine



Pharmacokinetic interaction unlikely1



Fluvoxamine



Substantially increased peak serum concentration and AUC of ramelteon1



Avoid concomitant use1



Ketoconazole



Increased peak serum concentration and AUC of ramelteon and active metabolite1



Use concomitantly with caution1



Midazolam



Pharmacokinetic interaction unlikely1



Omeprazole



Pharmacokinetic interaction unlikely1



Rifampin



Decreased peak serum concentration and AUC of ramelteon and active metabolite1



Concomitant use may reduce efficacy of ramelteon1 2



Theophylline



Pharmacokinetic interaction unlikely1



Warfarin



Pharmacokinetic interaction unlikely1



Urine Drug Screening



No false-positive results for urine drug screening of benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines1


Ramelteon Pharmacokinetics


Absorption


Bioavailability


Rapidly absorbed; following oral administration in fasting state, peak serum concentrations occur at approximately 0.75 hour.1


Total absorption is ≥84%; however, absolute oral bioavailability is 1.8% because of extensive first-pass metabolism.1


Food


High-fat meal delays time to peak serum concentration by 45 minutes, reduces peak serum concentration by 22%, and increases AUC by 31%.1 (See Oral Administration under Dosage and Administration.)


Special Populations


In geriatric patients, peak serum concentrations and AUC of ramelteon are increased by 86 and 97%, respectively.1 Peak serum concentrations and AUC of active metabolite also are increased, but to a lesser extent.1


In patients with mild or moderate hepatic impairment, exposure to ramelteon is increased 4- or 10-fold, respectively.1 Exposure to active metabolite is marginally increased.1 Pharmacokinetic parameters not evaluated in patients with severe hepatic impairment (Child-Pugh class C).1 (See Hepatic Impairment under Cautions.)


Pharmacokinetic parameters not altered in patients with renal impairment or in those requiring chronic hemodialysis.1


Distribution


Extent


Extensively distributed into tissues; not distributed selectively to red blood cells.1


Plasma Protein Binding


Approximately 82% (mainly [70%] albumin).1


Elimination


Metabolism


Metabolized principally by CYP1A2 and, to a lesser extent, by the CYP2C subfamily and by CYP3A4 to active (M-II) and inactive metabolites.1


Elimination Route


Excreted in urine (84%) and feces (4%), principally as metabolites.1


Half-life


1–2.6 hours (for ramelteon) and 2–5 hours (for active metabolite).1


Stability


Storage


Oral


Capsules

Tightly-closed containers at 25°C (may be exposed to 15–30°C).1 Protect from moisture and humidity.1


Actions



  • Exhibits high affinity for melatonin MT1 and MT2 receptors.1 2 Agonist activity at these receptors may contribute to the drug’s sleep-inducing properties.1 2




  • Demonstrates lower selectivity for melatonin MT3 receptors than for MT1 and MT2 receptors.1 Has no appreciable affinity for the GABA receptor complex or for receptors that bind neuropeptides, cytokines, serotonin, dopamine, norepinephrine, acetylcholine, or opiates.1



Advice to Patients



  • Necessity of administering within 30 minutes of bedtime and limiting activities to only those necessary to prepare for bed.1 Avoid administration with or immediately after a high-fat meal.1




  • Necessity of avoiding driving, operating machinery, or performing hazardous tasks following administration.1 Importance of avoiding alcohol during therapy.1




  • Importance of consulting a clinician if worsening insomnia or emergence of new behavioral manifestations occurs.1




  • Importance of consulting a clinician if cessation of menses or galactorrhea (in women), decreased libido, or problems with fertility occur.1




  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1




  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.1




  • Importance of informing patients of other important precautionary information.1 (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.













Ramelteon

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Tablets, film-coated



8 mg



Rozerem



Takeda


Comparative Pricing


This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 10/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.


Rozerem 8MG Tablets (TAKEDA PHARMACEUTICALS): 30/$171.00 or 90/$472.99



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions October 27, 2011. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.




References



1. Takeda Pharmaceuticals America, Inc. Rozerem (ramelteon) tablets prescribing information. Lincolnshire, IL; 2005 Aug.



2. Takeda Pharmaceuticals America, Inc., Lincolnshire, IL: Personal communication.



3. Zammit G, Roth T, Erman M et al. Double-blind, placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia. Sleep. 2005; 28(Suppl):A228-9.



4. Roth T, Seiden D, Weigand S et al. Phase III study to determine the efficacy of ramelteon in elderly patients with chronic insomnia. Proceedings of New Clinical Drug Evaluation Unit. June 6-9, 2005, Boca Raton, Fla. Poster abstract.



5. Roth T, Seiden D, Zee P et al. Phase III outpatient trial of ramelteon for the treatment of chronic insomnia in elderly patients. J Am Geriatr Soc. 2005; 53(Suppl):S25. Abstract.



6. Food and Drug Administration. Rozerem (ramelteon) tablets. [March 14, 2007: Takeda] MedWatch drug labeling changes. Rockville, MD; April 2007. From FDA websites () and ().



More Ramelteon resources


  • Ramelteon Side Effects (in more detail)
  • Ramelteon Use in Pregnancy & Breastfeeding
  • Ramelteon Drug Interactions
  • Ramelteon Support Group
  • 29 Reviews for Ramelteon - Add your own review/rating


  • Ramelteon MedFacts Consumer Leaflet (Wolters Kluwer)

  • Ramelteon Professional Patient Advice (Wolters Kluwer)

  • ramelteon Advanced Consumer (Micromedex) - Includes Dosage Information

  • Rozerem Prescribing Information (FDA)

  • Rozerem Consumer Overview



Compare Ramelteon with other medications


  • Insomnia

Monday, 26 September 2016

Menotropins




In the US, Menotropins (menotropins systemic) is a member of the drug class gonadotropins and is used to treat Female Infertility, Follicle Stimulation and Ovulation Induction.

US matches:

  • Menotropins

  • Menotropins injectable

Scheme

USAN

CAS registry number (Chemical Abstracts Service)

0009002-68-0

Therapeutic Category

Pituitary gonadotropin

Foreign Names

  • Menotropin (German)
  • Ménotropine (French)

Generic Names

  • Gonadotropine hypophysaire (OS: DCF)
  • Menotrophin (OS: BAN)
  • Ménotropine (OS: DCF)
  • Menotropins (OS: USAN)
  • Gonadotrophine hypophysaire (IS: DCF vieille)
  • Gonadotropinum hypophysicum (IS)
  • HMG (IS)
  • HPMG (IS)
  • Human Menopausal Gonadotrophins (IS)
  • Urogonadotropin (IS)
  • Menotrophin (PH: BP 2010)
  • Menotropina (PH: F.U. IX)
  • Menotropins (PH: USP 32)

Brand Names

  • Fertinorm P
    Merck Serono, Japan


  • Folyrmon P
    Fuji Yakuhin, Japan


  • Gonadoryl
    Mochida, Japan


  • Gonapure
    ASKA SeiyakuAsuka, Japan


  • HMG Lepori
    Farma Lepori, Spain


  • HMG Massone
    Quality, Peru


  • HMG
    ASKA SeiyakuAsuka, Japan; Fuji Yakuhin, Japan; Nikken, Japan


  • Humegon
    Organon, United Arab Emirates; Organon, Bahrain; Organon, Cyprus; Organon, Egypt; Organon, Ghana; Organon, Ireland; Organon, Iraq; Organon, Iran; Organon, Jordan; Organon, Japan; Organon, Kenya; Organon, Kuwait; Organon, Lebanon; Organon, Sri Lanka; Organon, Luxembourg; Organon, Libya; Organon, Qatar; Organon, Saudi Arabia; Organon, Sudan; Organon, Syria; Organon, Tanzania; Organon, Yemen; Organon, Zambia; Organon, Zimbabwe


  • Humog
    GP Pharm, Peru


  • Menogon
    Ferring, United Arab Emirates; Ferring, Bahrain; Ferring, Czech Republic; Ferring, Germany; Ferring, Egypt; Ferring, Greece; Ferring, Hong Kong; Ferring, Israel; Ferring, Italy; Ferring, Jordan; Ferring, Kuwait; Ferring, Lebanon; Ferring, Oman; Ferring, Poland; Ferring, Qatar; Ferring, Romania; Ferring, Saudi Arabia; Ferring, Singapore; Ferring, Syria; Ferring, Thailand; Ferring, Turkey; Ferring, Yemen


  • Menopur
    ARIS, Turkey; Dr. Fisher, Netherlands; EU-Pharma, Netherlands; Euro, Netherlands; Ferring, Argentina; Ferring, Austria; Ferring, Belgium; Ferring, Canada; Ferring, Switzerland; Ferring, Czech Republic; Ferring, Denmark; Ferring, Spain; Ferring, Finland; Ferring, France; Ferring, United Kingdom; Ferring, Greece; Ferring, Hong Kong; Ferring, Hungary; Ferring, Ireland; Ferring, Israel; Ferring, Iceland; Ferring, Luxembourg; Ferring, Luxembourg; Ferring, Netherlands; Ferring, Norway; Ferring, Oman; Ferring, Portugal; Ferring, Serbia; Ferring, Sweden; Ferring, Slovakia; Ferring, Tunisia; Ferring, Taiwan; Ferring, United States; Ferring, South Africa; Ferring Pharmaceuticals, Poland; PharmaSwiss, Croatia (Hrvatska); PharmaSwiss, Slovenia


  • Merapur
    Ferring, Mexico


  • Merional
    ARIS, Turkey; Faran Laboratories, Greece; IBSA, Switzerland; IBSA, Czech Republic; IBSA, Hungary; IBSA, Oman; IBSA, Serbia; IBSA, Slovakia; Pharmasure, United Kingdom


  • Meropur
    Ferring, Italy


  • Pergonal
    Serono, Luxembourg; Serono, Peru; Serono, Russian Federation; Serum Institute, India; Teva, Israel


  • Pregnorm
    Win-Medicare, India


  • Repronex
    Ferring, Canada; Ferring, United States

International Drug Name Search

Glossary

BANBritish Approved Name
DCFDénomination Commune Française
ISInofficial Synonym
OSOfficial Synonym
PHPharmacopoeia Name
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Trandolapril-DP




Trandolapril-DP may be available in the countries listed below.


Ingredient matches for Trandolapril-DP



Trandolapril

Trandolapril is reported as an ingredient of Trandolapril-DP in the following countries:


  • Australia

International Drug Name Search